Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05961137
Other study ID # 1-1260269-1
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 1, 2021
Est. completion date August 31, 2022

Study information

Verified date July 2023
Source Orange Park Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this quality improvement study is to measure the impact of incorporation of a manual rapid fluid infuser (RFI) for intravenous crystalloid infusion in patients with suspected sepsis in the prehospital interval. The main question[s] it aims to answer are: - Does the intervention affect the timeliness of fluid administration? - Does the intervention affect CMS sepsis bundle care measure compliance? - Does the intervention affect processes and outcomes of care? - Are there any adverse effects? Researchers will compare this intervention to use of more conventional gravity or pressure-infusion bag crystalloid infusion.


Recruitment information / eligibility

Status Completed
Enrollment 66
Est. completion date August 31, 2022
Est. primary completion date December 31, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Patients meeting sepsis alert criteria who were transported to the study hospital's emergency department by one of the four rescue units involved in the study. Sepsis alert defined as patient has suspected infection and two or more of the following: (a) temperature > 38° C (100.4° F) or < 36° C (96.8° F), (b) respiratory rate > 20 breaths / minute or end-tidal carbon dioxide (ETCO2) = 25 mmHg, or (c) heart rate > 90 beats / minute Exclusion Criteria: - prehospital trauma - prehospital cardiac arrest prior to signaling sepsis alert - interfacility transfer - emergency transport from medical facility (e.g., medical office or clinic) - intervention by medical practitioner before emergency medical services arrival - do not resuscitate order in place

Study Design


Intervention

Other:
Incorporation of Rapid Fluid Infusion Device in Prehospital Suspected Sepsis Protocol
Modified protocol specifying intravenous crystalloid infusion Rapid Fluid Infusion Device. The protocol states that for patients meeting the sepsis alert criterion, EMS will provide basic medical care, oxygen, a 12-lead electrocardiogram, attempt placement of an IV catheter and initiate administration of 30mL/kg of fluids.
Conventional Prehospital Suspected Sepsis Protocol
Conventional protocol employing intravenous crystalloid infusion via gravity or pressurized-bag. The protocol states that for patients meeting the sepsis alert criterion, EMS will provide basic medical care, oxygen, a 12-lead electrocardiogram, attempt placement of an IV catheter and initiate administration of 30mL/kg of fluids.

Locations

Country Name City State
United States Orange Park Medical Center Orange Park Florida

Sponsors (2)

Lead Sponsor Collaborator
Orange Park Medical Center 410 Medical

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage compliance with the CMS 3-hour sepsis bundle criterion (SEP-1) for patients with suspected sepsis As defined according to the Centers for Medicare and Medicaid Services (CMS) Specifications Manual for Hospital Inpatient Quality Measures, version 5.9. "Time of presentation" or "time-zero" was defined as the time of triage in the Emergency Department. All patients enrolled in the study were assessed for measure compliance, without application of measure inclusion/exclusion criteria. Assessed at 3 hours after ED arrival
Secondary Percentage achievement of 30mL/kg crystalloid infusion for hypotension or lactate level > 4 mmol/L at 1 hour Dichotomous measure of whether infusion volume was met, based on sum of prehospital and ED-based crystalloid fluid infusion Assessed at 1 hour after ED arrival
Secondary Total volume of intravenous crystalloid infused by time of ED arrival During the 3 hours prior to ED arrival, while under care by EMS.
Secondary Total volume of intravenous crystalloid infused by 1 hour after ED arrival Assessed at 1 hour after ED arrival
Secondary Total volume of intravenous crystalloid infused by 3 hours after ED arrival Assessed at 3 hours after ED arrival
Secondary Total volume of intravenous crystalloid infused, in the ED, by 1 hour after ED arrival Assessed at 1 hour after ED arrival
Secondary Total volume of intravenous crystalloid infused, in the ED, by 3 hours after ED arrival Assessed at 3 hours after ED arrival
Secondary Percentage of study participants receiving any intensive care unit care Through discharge from index acute-care episode, up to 6 months
Secondary Percentage of study participants with admission disposition during index ED visit Through discharge from index acute-care episode, up to 6 months
Secondary Percentage of enrollees receiving any specified life-support interventions in the first 24 hours from ED arrival Specified life-support interventions were mechanical ventilation, vasopressor use, cardiopulmonary resuscitation, surgical intervention. Assessed at 24 hours after ED arrival
Secondary Percentage of enrollees experiencing in-hospital death Through discharge from index acute-care episode, up to 6 months
Secondary Total length of stay in ED Operationalized as time difference between ED clinician's documented disposition time and the patient's arrival time. Through discharge from index acute-care episode, up to 6 months
Secondary Total length of stay in hospital Among those admitted to the hospital as the disposition of their index ED visit. Through discharge from index acute-care episode, up to 6 months
Secondary Total length of stay in intensive care unit Through discharge from index acute-care episode, up to 6 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05095324 - The Biomarker Prediction Model of Septic Risk in Infected Patients
Completed NCT02714595 - Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens Phase 3
Completed NCT03644030 - Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
Completed NCT02867267 - The Efficacy and Safety of Ta1 for Sepsis Phase 3
Completed NCT04804306 - Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
Recruiting NCT05578196 - Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections. N/A
Terminated NCT04117568 - The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
Completed NCT03550794 - Thiamine as a Renal Protective Agent in Septic Shock Phase 2
Completed NCT04332861 - Evaluation of Infection in Obstructing Urolithiasis
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Enrolling by invitation NCT05052203 - Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Completed NCT03258684 - Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock N/A
Recruiting NCT05217836 - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Completed NCT05018546 - Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery N/A
Completed NCT03295825 - Heparin Binding Protein in Early Sepsis Diagnosis N/A
Not yet recruiting NCT06045130 - PUFAs in Preterm Infants
Not yet recruiting NCT05361135 - 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia N/A
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3